Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells

Journal of Controlled Release

Volumn 131, Issue 2, 2008, Pages 100-106

  Garmann, Dirk ^a   Warnecke, André ^b   Kalayda, Ganna V ^a   Kratz, Felix ^b   Jaehde, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

^b TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Accumulation; Cisplatin; Endocytosis; Macromolecular platinum complexes; Resistance

Indexed keywords

CHEMOTHERAPY; CHLORINE COMPOUNDS; ETHYLENE GLYCOL; GLYCOLS; MACROMOLECULES; MECHANISMS; PLATINUM; POLYETHYLENE GLYCOLS;

ACCUMULATION; CANCER CHEMOTHERAPIES; CELLULAR UPTAKE; CISPLATIN; ENDOCYTOSIS; MACROMOLECULAR PLATINUM COMPLEXES; OVARIAN CARCINOMA CELLS; PLATINUM COMPLEXES; PRODRUGS; RESISTANCE; RESISTANCE MECHANISMS; TUMOR CELLS; UPTAKE MECHANISMS;

PLATINUM COMPOUNDS;

ALBUMIN; BAFILOMYCIN A1; CISPLATIN; CLATHRIN; MACROGOL; METHYL BETA CYCLODEXTRIN; PLATINUM;

ARTICLE; CAVEOLA; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; ENDOCYTOSIS; HUMAN; HUMAN CELL; HYDROLYSIS; INCUBATION TIME; MACROMOLECULE; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; HYDROLYSIS; MOLECULAR STRUCTURE; ORGANOPLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; SERUM ALBUMIN; SERUM ALBUMIN, BOVINE; SPECTROPHOTOMETRY, ATOMIC;

EID: 53049106223     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.07.017     Document Type: Article

References (40)

1. Highley M.S., and Calvert A.H. Clinical experience with cisplatin and carboplatin. In: Kelland L., and Farrel N. (Eds). Platinum Based Drugs in Cancer Therapy (2000), Humana Press, Totowa, New Jersey 171-194
2. O'Dwyer P.J., Stevenson J.P., and Johnson S.W. Clinical experience: DACH-based platinum dugs. In: Kelland L., and Farrel N. (Eds). Platinum Based Drugs in Cancer Therapy (2000), Humana Press, Totowa, New Jersey 231-245
3. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 47 (2003) 7265-7279
4. Akiyama S., Chen Z.S., Sumizawa T., and Furukawa T. Resistance to cisplatin. Anticancer Drug Des. 14 2 (1999) 143-151
5. Jordan P., and Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell. Mol. Life Sci. 57 8-9 (2000) 1229-1235
6. Holzer A.K., Samimi G., Katano K., Naerdemann W., Lin X., Safaei R., and Howell S.B. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 66 4 (2004) 817-823
7. Holzer A.K., Manorek G.H., and Howell S.B. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol. Pharmacol. 70 4 (2006) 1390-1394
8. Katano K., Kondo A., Safaei R., Holzer A., Samimi G., Mishima M., Kuo Y.M., Rochdi M., and Howell S.B. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res. 62 22 (2002) 6559-6565
9. Komatsu M., Sumizawa T., Mutoh M., Chen Z.S., Terada K., Furukawa T., Yang X.L., Gao H., Miura N., Sugiyama T., and Akiyama S. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res. 60 5 (2000) 1312-1316
10. Safaei R., and Howell S.B. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Oncol. Hematol. 53 1 (2005) 13-23
11. Safaei R. Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett. 234 1 (2006) 34-39
12. Zisowsky J., Koegel S., Leyers S., Devarakonda K., Kassack M.U., Osmak M., and Jaehde U. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem. Pharmacol. 73 2 (2007) 298-307
13. Fang J., Sawa T., and Maeda H. Factors and mechanism of "PR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv. Exp. Med. Biol. 519 (2003) 29-49
14. Greish K., Fang J., Inutsuka T., Nagamitsu A., and Maeda H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin. Pharmacokinet. 42 13 (2003) 1089-1105
15. Maeda H., Fang J., Inutsuka T., and Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3 3 (2003) 319-328
16. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., and Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89 3 (1998) 307-314
17. Sinn H., Schrenk H.H., Friedrich E.A., Schilling U., and Maier-Borst W. Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I, Int. J. Rad. Appl. Instrum. B 17 8 (1990) 819-827
18. Stehle G., Sinn H., Wunder A., Schrenk H.H., Stewart J.C., Hartung G., Maier-Borst W., and Heene D.L. Plasma protein (albumin) catabolism by the tumor itself - implications for tumor metabolism and the genesis of cachexia. Crit Rev. Oncol. Hematol. 26 2 (1997) 77-100
19. Tanaka T., Shiramoto S., Miyashita M., Fujishima Y., and Kaneo Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. J. Pharm. 277 1-2 (2004) 39-61
20. Warnecke A., Fichtner I., Garmann D., Jaehde U., and Kratz F. Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug carboplatin designed as albumin-binding prodrugs. Bioconjug. Chem. 5 6 (2004) 1349-1359
21. Aronov O., Horowitz A.T., Gabizon A., and Gibson D. Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjug. Chem. 14 3 (2003) 563-574
22. Pasini A., Caldirola C., Spinelli S., and Valsecchi M. Comments on different synthetic methods for the preparation of diamine and bis(amine) organodicarboxylatoplatinum(II) complexes. Synth. React. Inorg. Met.-Org. Chem. 23 6 (1993) 1021-1060
23. Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R., Whang-Peng J., Louie K.G., Knutsen T., McKoy W.M., Young R.C., and Ozols R.F. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47 2 (1987) 414-418
24. Mueller H., Kassack M.U., and Wiese M. Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. J Biomol. Screen. 9 6 (2004) 506-515
25. Kloft C., Appelius H., Siegert W., Schunack W., and Jaehde U. Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay. Ther. Drug Monit. 21 6 (1999) 631-637
26. Yumoto R., Nishikawa H., Okamoto M., Katayama H., Nagai J., and Takano M. Clathrin-mediated endocytosis of FITC-albumin in alveolar type II epithelial cell line RLE-6TN. Am. J. Physiol. Lung Cell Mol. Physiol. 290 5 (2006) L946-L955
27. Guo Y., Smith K., and Petris M.J. Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: requirement for the extracellular methionine-rich clusters. J. Biol. Chem. 279 45 (2004) 46393-46399
28. Holzer A.K., Katano K., Klomp L.W., and Howell S.B. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin. Cancer Res. 10 19 (2004) 6744-6749
29. Chauhan S.S., Liang X.J., Su A.W., Pai-Panandiker A., Shen D.W., Hanover J.A., and Gottesman M.M. Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br. J. Cancer 88 8 (2003) 1327-1334
30. Liang X.J., Mukherjee S., Shen D.W., Maxfield F.R., and Gottesman M.M. Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Res. 66 4 (2006) 2346-2353
31. Marverti G., and Andrews P.A. Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells. Clin. Cancer Res. 2 6 (1996) 991-999
32. Ayesu K., and Andrews P.A. Role of receptor mediated endocytosis in cisplatin accumulation. Proc. Am. Assoc. Cancer. Res. 37 (1996) 403
33. Conner S.D., and Schmid S.L. Regulated portals of entry into the cell. Nature 422 6927 (2003) 37-44
34. Nelson N., and Harvey W.R. Vacuolar and plasma membrane proton-adenosinetriphosphatases. Physiol Rev. 79 2 (1999) 361-385
35. Hryciw D.H., Ekberg J., Ferguson C., Lee A., Wang D., Parton R.G., Pollock C.A., Yun C.C., and Poronnik P. Regulation of albumin endocytosis by PSD95/Dlg/ZO-1 (PDZ) scaffolds. Interaction of Na+-H+ exchange regulatory factor-2 with ClC-5. J. Biol. Chem. 281 23 (2006) 16068-16077
36. Neufeld E.B., Cooney A.M., Pitha J., Dawidowicz E.A., Dwyer N.K., Pentchev P.G., and Blanchette-Mackie E.J. Intracellular trafficking of cholesterol monitored with a cyclodextrin. J. Biol. Chem. 271 35 (1996) 21604-21613
37. Orlandi P.A., and Fishman P.H. Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains. J. Cell Biol. 141 4 (1998) 905-915
38. Sasaki Y., Nagai J., Kitahara Y., Takai N., Murakami T., and Takano M. Expression of chloride channel, ClC-5, and its role in receptor-mediated endocytosis of albumin in OK cells. Biochem. Biophys. Res. Commun. 282 1 (2001) 212-218
39. Andrews P.A. Cisplatin accumulation. In: Kelland L., and Farrel N. (Eds). Platinum based Drugs in Cancer Therapy (2000), Humana Press, Totowa, New Jersey 89-113
40. Sharp S.Y., Mistry P., Valenti M.R., Bryant A.P., and Kelland L.R. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B. Cancer Chemother. Pharmacol. 35 2 (1994) 137-143